Melatonin has a two different mechanism of action to prevent pro-amyloidogenic environment that leads to Alzheimer's amyloid β (Aβ) amyloidosis: (1) anti-amyloidogenic and (2) anti-oxidant properties. The former causes the reduction of the β-sheet-rich conformer which becomes aggregated and neurotoxic, contributing to neuroprotection. The latter also results in the reduction of neuronal damage mediated by Aβ-mediated oxidative stress. These strong neuroprotective effects may bear relevance to pathogenesis and therapy of Alzheimer's disease (AD). This review focuses on melatonin as a therapeutic agent for Alzheimer's disease.
- Alzheimer's disease
- Amyloid β
- Anti-amyloidogenic properties of melatonin
- Antioxidant properties of melatonin
ASJC Scopus subject areas
- General Medicine